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Abstract
Purpose of review
A recent American Academy of Neurology Evidence-Based Practice
Guideline on vestibular myogenic evoked potential (VEMP) testing has described superior canal dehiscence syndrome (SCDS) and
evaluated the merits of VEMP in its diagnosis. SCDS is an uncommon but now well-recognized cause of dizziness and auditory
symptoms. This article familiarizes health care providers with this
syndrome and the utility and shortcomings of VEMP as a diagnostic
test and also explores payment policies for VEMP.
Recent findings
In carefully selected patients with documented history compatible with the SCDS, both highresolution temporal bone CT scan and VEMP are valuable aids for diagnosis. Payers might be
unfamiliar with both this syndrome and VEMP testing.
Summary
It is important to raise awareness of VEMP and its possible indications and the rationale for
coverage of VEMP testing. Payers may not be readily receptive to VEMP coverage if this test is
used in an undiﬀerentiated manner for all common vestibular and auditory symptoms.

VEMP is a relatively new vestibular function test performed by stimulating one ear with repetitive
pulse or click sound stimulation and then measuring surface EMG responses over selected
muscles averaging the reaction of the muscle electrical activity associated with each sound click or
pulse. The clinical application of VEMP was ﬁrst reported by Colebach in 1994 but had its basis in
even earlier work in the vestibular ﬁeld.1 While VEMP testing has been increasingly used
throughout the world, its use in the United States has been more limited. Recently, the American
Academy of Neurology published an evidence-based practice guideline on the use of VEMP. In
addition, in October 2015 the FDA approved VEMP equipment by GN Otometrics
(Schaumburg, IL) for sale in the United States. In March 2017, Interacoustics (Middelfart,
Denmark) and in September 2017 Intelligent Hearing Systems (Miami, FL) were also granted
FDA approval to market VEMP equipment sales. This article is intended to help clinicians
incorporate the conclusions of the recently published practice guideline2 and to oﬀer special
attention to payment policy issues for this new diagnostic test.
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VEMP serves as a physiologic
confirmation in those suspected of
having SCDS and is a useful adjunct to
the temporal bone CT.

Major guideline ﬁndings
The guideline related to VEMP use in the diagnosis of SCDS
concluded that clinicians may use cVEMP stimulus threshold
values to distinguish SCDS from controls and that corrected
cVEMP amplitude may be used to distinguish SCDS from
controls. In addition, clinicians may use oVEMP amplitude to
distinguish SCDS from normal controls and oVEMP threshold
may be used to aid in distinguishing SCDS from controls.
Table 1 outlines sensitivity and speciﬁcity data from the
guideline. It was also concluded that there is currently insuﬃcient evidence to determine whether cVEMP and oVEMP
can accurately identify vestibular function speciﬁcally related to
the saccule/utricle, or whether cVEMP or oVEMP is useful in
diagnosing vestibular neuritis or Ménière disease (Level C).
There are 2 types of VEMP testing: cVEMP and oVEMP. A
sound stimulus applied to one ear evokes a response within
the ipsilateral sternocleidomastoid muscles that can be
recorded with surface electrodes and averaged (cVEMP)
(ﬁgure 1A). Similarly, a sound stimulus to the ear also evokes
a response that is largest when recorded from the contralateral inferior oblique muscle recorded by a surface electrode and averaged (oVEMP) (ﬁgure 1B).
VEMP serves as a physiologic conﬁrmation in those suspected of
having SCDS and is a useful adjunct to the temporal bone CT.
Superior canal dehiscence syndrome
SCDS is an uncommon syndrome due to an abnormal
opening or dehiscence in the bony roof of the superior
semicircular canal in the temporal bone.4 In contrast to other
more well-recognized diagnoses capable of causing vertigo,

SCDS is an unfamiliar entity to many. This unfamiliarity
leads to under-recognition of the entity. This condition may
present with excessive sound sensitivity, sometimes by pulsatile tinnitus as well as a variety of sensations of dizziness
including dizziness evoked or triggered by changes in sound
or pressure.5
Suspecting SCDS
There are no established diagnostic criteria for SCDS but
clinical suspicion should be piqued by a report of dizziness
induced by coughing, sneezing, straining, or loud sounds.
Hearing one’s own bone-conducted sounds such as pulse,
footsteps, or speech is another typical feature (autophony).
Dizziness caused by sounds, vibration, and altitude changes
along with sound sensitivity can be suggestive of SCDS and
prompt workup with thin cut temporal bone imaging looking
for the appearance of dehiscence. High-resolution CT of the
temporal bone is typically needed for the diagnosis and is
essential before consideration of surgical intervention.
False-positives have been reported with temporal bone CT
studies.6,7 CT may overcall the anatomic ﬁnding of dehiscence because of a number of technical factors.8 Moreover, an opening in the bone over the superior canal
(superior canal dehiscence [SCD]) may not actually transmit pressure until the dura becomes suﬃciently elastic (e.g.,
from aging or trauma). Thus, VEMP testing may aid in the
diagnosis by serving as a physiologic correlate to the anatomic appearance on temporal bone CT. By combining
temporal bone CT with VEMP, it appears very likely that the
diagnostic accuracy for SCDS will improve.5 In properly
diagnosed instances of SCDS, surgical repair of the dehiscence carries a high rate of successful relief of symptoms9
and normalization of VEMP abnormalities.10
Without clear documentation, by history and examination,
the rationale for suspecting the presence of SCDS and the
legitimacy for testing become tenuous.
A discriminating pretest clinical evaluation for symptom severity is critical in promoting shared decision-making.

Table 1 Sensitivity and specificity findings of the practice guideline on vestibular evoked myogenic potential (VEMP)
testing for superior canal dehiscence syndrome (SCDS)2
Sensitivity,a %

Specificity,a %

Level of recommendation

86–91

90–96

Possibly predictive of SCDS (Level C)b

Corrected cervical VEMP amplitude >2 SD greater than
that of controls

100

93

Possibly predictive of SCDS (Level C)

Ocular VEMP threshold <2 SD below that of controls

77–100

77–100

Possibly predictive of SCDS (Level C)

Ocular VEMP amplitude >2 SD greater than controls

77–100

98–100

Possibly predictive of SCDS (Level C)

Test measure for diagnosis of SCDS
Cervical VEMP threshold <2 SD below that of controls

a
b
c
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c

Values of sensitivity and specificity are for distinguishing those with SCDS from healthy controls.
Level of recommendation as described in Edlund et al.3
Normative values based on control patients should be established in each individual laboratory.
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Figure 1 Waveform for cervical vestibular evoked myogenic potential (VEMP) and for ocular VEMP

(A) Cervical VEMP. (B) Ocular VEMP.

Patients who choose to have surgery have more severe presurgical autophony, auditory, or vestibular symptoms.11
Diagnosing SCDS
As of now, other than the clinical evaluation, there is no
established reference test (gold standard) against which a putative diagnostic procedure for SCDS can be evaluated. In diagnostic medicine, the availability of an incomplete or absent
reference standard is not an unfamiliar situation. Generally
a diagnostic test, even if less than perfect, by virtue of its earlier
appearance and longevity becomes the reference standard. In
the absence of a perfect reference standard, some alternatives
may serve in lieu of a rigid gold standard for making decisions.
They are as follows: results of several tests, an “umpire” test,
natural history of the disease process, and clinical follow-up and
prognosis after treatment.12-15 In SCDS, surgery can conﬁrm
the anatomic ﬁnding of dehiscence. Resolution of symptoms
along with normalization of physiologic abnormalities after
repair also conﬁrms a role of VEMPs in the diagnosis of
SCDS.10 Until remaining uncertainties clear, newer diagnostic
technologies deserve periodic evaluations rather than outright
acceptance or rejection.
Diagnostic algorithm options
There is no established algorithm for the best way to diagnose and conﬁrm SCDS. Figures 2 and 3 show 2 reasonable algorithms for diagnosing clinically suspected instances
of SCD based on current evidence. The ﬁrst suggestion is to
perform high-resolution CT scans of the temporal bone
followed by a conﬁrmatory VEMP, especially when surgery
is planned. The second is to carry out VEMP testing as
a screening test with a subsequent CT scan if the VEMP is
anything other than normal, especially when surgery is being
considered. One of these diagnostic pathways or perhaps
another will be clariﬁed with more clinical experience and
over time.
Arguments in support of performing VEMP
The above sequence for suspecting, diﬀerentiating, and diagnosing SCDS is valuable in seeking insurance coverage
either prior to a procedure or building an argument against
Neurology.org/CP

denial of payment after a test has been performed. It is important for clinicians to ensure a solid prior probability before
ordering VEMP. This sets a convincing backdrop to show
that VEMP is not used by the provider as a routine indiscriminate test in persons with the rather common clinical
complaints of dizziness, tinnitus, hearing diﬃculties, or imbalance. Such nonspeciﬁc use of VEMPs will dilute the value
of the test, and subsequently solidify payers’ notions that
these tests are of low health beneﬁt.
However, clinicians who evaluate patients for vertigo or dizziness know that it is rare that one test clinches the diagnosis (e.g.,
Dix-Hallpike testing for benign paroxysmal positional vertigo
[BPPV]). Instead, in the majority of cases, diagnosis arises from
the recognition of syndromic patterns from the history, examination, and quantitative testing. For example, a patient with
superior vestibular neuritis has about a 30% chance of developing posterior canal BPPV subsequently,16 which is believed to be due to release of otoconia from inﬂammation that
became located in the posterior canal to cause BPPV. Here an
intact cVEMP is expected since the inferior vestibular nerve
supplies the posterior canal and the saccule is still functional
and could cause subsequent BPPV. Such a case illustrates that
cVEMP may have important diagnostic and management
implications, even though it is not diagnostic in isolation.
Advantages of VEMP
VEMP is a noninvasive safe test that is similar to other
established evoked potential tests already in use. Its helpfulness in clarifying the correct diagnosis can result in improved outcomes. Surgery for SCDS, based on large case
series, indicates a good level of success in alleviating symptoms with very low failure rates when properly diagnosed. Its

VEMP is a noninvasive safe test that is
similar to other established evoked
potential tests already in use.
Neurology: Clinical Practice | Volume 8, Number 2 | April 2018
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Figure 2 One reasonable algorithm option for using vestibular evoked myogenic potential (VEMP) in the
diagnosis of superior canal dehiscence syndrome (SCDS)

Figure 3 A second reasonable algorithm option for use of
vestibular evoked myogenic potential (VEMP) in
making the diagnosis of superior canal dehiscence syndrome (SCDS)

cVEMP = cervical VEMP; oVEMP = ocular VEMP.
cVEMP = cervical VEMP; oVEMP = ocular VEMP.

utilization is unlikely to be high when utilized narrowly to aid
in the diagnosis of SCDS.
Disadvantages or limitations of VEMP
The lack of a perfect diagnostic reference standard becomes
a persuasive argument for mindful selection of patients for
VEMP testing. In view of the very satisfactory rate of symptom resolution with surgical repair, attention to historical
details and conﬁrmation through one of the diagnostic
pathways is necessary prior to surgery. Awareness of the
potential for indiscriminate testing for nonspeciﬁc auditoryvestibular symptoms is essential. It is not unreasonable to
expect payer scrutiny due to overutilization of testing modalities. This advice is especially applicable to unfamiliar, underrecognized symptom complexes and newer test modalities.

Current coverage policies
Medicare contractors may elect to question the need for
VEMPs not only because of unfamiliarity but also due to the
ﬁndings of variable accuracy in older persons. Consequently,
private payers should not wait for CMS or Medicare administrative contractors to issue coverage determinations but
rather develop their own coverage policies based on the
current literature.

There are no dedicated procedure codes assigned to cVEMP
or oVEMP. The comparability to BAEP is likely to ease
comprehension of concepts by payers. In the meantime,
patients should be issued a procedure-speciﬁc Advanced

Many insurance companies require prior authorization on
unlisted procedures in order for payment to be considered.
Several insurance companies have issued payment policies related to VEMP. Aetna payment policy, last reviewed on April 4,
2017, cites older reviews of vestibular testing from 200017 and
200618 indicating this modality is still investigational.19 Blue
Cross Blue Shield of Rhode Island policy, last updated on April
18, 2017, concludes that evidence is insuﬃcient to determine
the eﬀects of VEMP on health outcomes.20 Healthnet has
a national medical policy, last updated in July 2016, and does
not cover VEMP due to a lack of evidence from well-controlled
prospective clinical trials showing VEMP alters management or

Neurology: Clinical Practice | Volume 8, Number 2 | April 2018
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VEMP is an evoked potential test like auditory brainstem
responses (ABRs) though with less history, less familiarity in
clinical use, and no history of insurance coverage in the
United States. The technical and interpretive work of VEMP
is almost identical to ABRs.
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Beneﬁciary Notice of noncoverage to clarify that VEMP
procedures are not usually paid for by Centers for Medicare
& Medicaid Services (CMS) and by some other payers.
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Table 2 Suggestions for engaging in a payer dialogue when vestibular evoked myogenic potential (VEMP) test value
comes under review
1. Anticipate the need to explain to reviewers and payers both the entity of superior canal dehiscence syndrome and the nature of VEMPs.
2. Use appropriate sections of the guideline, and this article, for additional support.
3. Explain how your group/practice selects patients based on carefully elicited history characteristic of the syndrome. Be willing to produce appropriate
documentation.
4. Be prepared for discussion of situations where reference gold standards may not be available.
5. Stress the comparability of VEMP work (technical and interpretive) to more familiar evoked potential tests such as brainstem auditory evoked
potential testing.
6. Be aware of the absence of specific procedure codes for VEMP.

improves outcome.21 Paramount medical policy on vestibular
function testing from January 10, 2017, states that the US FDA
has not approved speciﬁc devices for VEMP testing (though, as
mentioned earlier, the FDA has now reversed its stance and has
approved devices from 2 separate companies). The policy
concludes that VEMP testing is investigational and therefore
not a covered procedure.22

Conclusions
VEMP testing and SCDS may be unfamiliar to many clinicians and payers. The recently published practice guideline
may use VEMP testing as a way of separating patients with
SCDS from controls, thus aiding in making the diagnosis of
SCDS. Additional research is needed to clarify how to best
use VEMP in arriving at a diagnosis of SCDS in clinical
practice. Figures 2 and 3 depict 2 reasonable algorithms for
use of VEMP in diagnosing SCDS. Table 1 summarizes
sensitivity and speciﬁcity data from the practice guideline
and table 2 oﬀers some suggestions in preparation for discussion with payers on the utility of VEMP testing for this
diagnosis. At present, there is insuﬃcient evidentiary support
for use of VEMP in general dizziness and so we would not
anticipate this to be heavily utilized save for the narrow indication of suspected SCDS unless new evidence emerges.
Due to lack of CPT code, one can anticipate coding as
a miscellaneous code would undergo focused medical review
by nongovernmental insurers. Clinicians must recognize and
be prepared to argue for the value of VEMPs in circumstances other than SCDS when the test may reﬁne diagnosis
and guide management. An appreciation for VEMPs in
a holistic evaluation of vestibular function, incorporating
history, neuro-otologic examination, and appropriate auditory and other quantitative vestibular testing, is essential in
arguing what is best for clinical care.

TAKE-HOME POINTS
Vestibular evoked myogenic potential (VEMP) testing is a relatively new vestibular testing technique
that determines vestibular function by applying
a repetitive sound stimulus to one ear and then
averaging the reaction of the muscle activity in
response to each sound click or pulse.
Unlike caloric testing or rotational chair testing,
VEMP does not measure eye movements. Surface
EMG recordings over the ipsilateral sternocleidomastoid muscle (cervical VEMP [cVEMP]) is believed
to assess function of the saccule. Surface EMG
recordings over the contralateral inferior oblique
(ocular VEMP [oVEMP]) is believed to assess
function of the utricle.
In a comprehensive evidence-based review of the
literature, weak evidence supports VEMP testing as
valuable in affirming the diagnosis of superior canal
dehiscence syndrome (SCDS) but so far, quality
evidence is limited for its routine use in other
vestibular disorders.
As a new test just approved by the Food and Drug
Administration (FDA) about 2 years ago and
currently without a specific billing procedure code
(i.e., Current Procedural Terminology [CPT] code), it
is anticipated that some payers will require clarification or explanation before approving payment
until payment policies are updated and a specific
CPT code is assigned.
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